Aldeyra's Allergy Drug Misses Endpoint But Company Sees Market Gap

Aldeyra is moving ahead with plans for Phase III trials of its novel allergy drug in the face of a missed Phase IIb endpoint. Its ultimate success could rest on what endpoint the FDA will accept.